Markets andneeds Potential customers include institutions and regions facing complex infectious disease diagnostics, where Akonni’s gel-drop microarray platform could address costs and scalability for MDR-TB and similar pathogens, presenting a compelling value proposition for government and public health buyers.

TechDifferentiator Leverage Akonni’s unique gel-drop microarray technology and high yield sample prep to position against conventional MDx players, highlighting cost per test, multiplexing capabilities, and instrumentation integration to win RFPs with tiered lab capabilities.

FundingMomentum Recent NIH SBIR/CRP grants and Frost & Sullivan award signals momentum and validation; target grant-funded programs, public health labs, and academia that prioritize innovation funding and early adoption for next-gen diagnostics.

StrategicPartners Opportunity to engage Righton and other strategic investors for scaling, while exploring OEM or co-development partnerships with established diagnostics distributors to accelerate market entry and expand regional coverage.

SMEFit Small to mid-sized biotech labs (11-50 employees) and regional diagnostic groups represent a fit for scalable manufacturing and affordable MDx solutions; tailor messaging around ease of deployment, training, and total cost of ownership to drive faster procurement.